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Background: This retrospective chart review investigated differences in the prevalence of medical comorbidity between women with fibromyalgia (FM) (n=219) and a control group women
with chronic pain (CP) without FM (n=116). The specific aims were to compare the prevalence
of autoimmune, psychiatric, endocrine, gynecologic pathology, the relationship between timing of gynecologic surgery, and pain onset. We additionally sought to compare the number of
comorbidities in an ethnically diverse cohort.
Methods: This was a retrospective chart review of patients seen in FM or CP clinics at an
academic medical center in 2009–2010.
Results: Logistic regression modeling found that gynecologic, endocrine, and autoimmune
diagnoses were independently associated with a diagnosis of FM. Detailed analyses showed that
thyroid disease (P,0.01) and gynecologic surgery (P,0.05) were significantly more common in
FM. Women with FM were more likely to have multiple autoimmune, endocrine, gynecologic, or
psychiatric pathologies. A relationship was observed between the timing of gynecologic surgery
and pain onset in FM, with more surgeries observed in the years just prior to pain onset or in
the year after pain onset. A similar pattern was not found in the control group.
Conclusion: This study demonstrates that autoimmune, endocrine, and gynecologic pathologies occur more commonly in women with FM than in those with CP, which is consistent with
findings in less ethnically diverse samples. Moreover, a relationship was found between timing
of pain onset and gynecologic surgery. A larger prospective study of the relationship between
gynecologic surgery and pain onset in FM is warranted.
Keywords: fibromyalgia, sex hormones, thyroid, autoimmune, chronic pain
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Fibromyalgia (FM) has a total prevalence of 2% in the general population and is disproportionately more common in women after the age of 50 years, with a female to
male ratio of 7:1.1 In women, the prevalence of FM is only 0.9% between the ages of
18 and 30 years, but increases sharply at the age of 40–60 years, 1 a period known for
hormonal changes in women. A higher prevalence of pain in women compared with
men is commonly reported across a number of pain conditions, including irritable
bowel syndrome,2,3 temporomandibular disorder,4,5 chronic musculoskeletal pain,6
and migraines.7 FM has been demonstrated to have a higher degree of comorbidity
with multiple conditions, including endocrine and genitourinary disorders, than in
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o steoarthritis and other rheumatologic conditions.8,9 FM
frequently accompanies autoimmune disorders10,11 which
also typically occur more commonly in women.
Several studies have assessed the presence of autoimmune disease in patients with FM and vice versa. There is
an increase in autoimmune thyroid disease and autoantibody
profile in FM patients,12 which has been proposed as a possible predisposing factor in the development of FM.13 The
clinical severity of FM is more severe in patients with positive thyroid antibodies, and post-menopausal FM patients
have a higher prevalence of thyroid antibodies than their
premenopausal counterparts.11 Elevated thyroid antibodies
are similarly seen in rheumatoid arthritis patients, which are
also significantly greater than in healthy controls,14 though
some studies indicate a greater frequency of antibodies in
rheumatoid arthritis patients than FM patients.15 There is
additionally an increased prevalence of FM in systemic
lupus erythematosus (SLE) patients and Sjogren patients,
with one study demonstrating FM in 32% of SLE patients
and 18% of Sjogren patients.16 FM is associated with worse
health status and an increase in psychiatric symptoms in SLE
patients.17 Interestingly, when analyzing the converse, there
appears to be no increase in the risk of developing SLE in
patients previously diagnosed with FM.13 Yet, there is a higher
prevalence of Raynaud’s phenomenon, sicca symptoms, and
autoantibodies in FM patients.18
The sex differences in the prevalence of chronic pain (CP)
conditions have generated multiple review articles about the role
of sex hormones in pain onset, maintenance, or inhibitory control.19–24 Though substantial evidence links gonadal hormones
and pain, the relationship between gonadal hormones and pain
is not fully understood. One study showed that estrogen may
have pronociceptive or antinociceptive effects depending on the
receptor.25 Sex steroids alter levels of neuromodulators involved
in spinal nociceptive processing, including substance P, amino
acids such as gamma aminobutyric acid, and glutamate and have
been shown to increase the number of excitatory synapses in
neurons in the cortex, cerebellum, and hippocampus.24 Several
studies have examined the relationship of gynecologic pathology
to FM. Some (but not all) studies have shown fluctuations in
pain levels depending on the menstrual cycle phase.20,26,27 Hysterectomies and early menopause additionally occur more commonly in FM patients than in rheumatoid arthritis controls.28,29
Interestingly, Warren et al have noted an increased frequency of
hysterectomies in patients developing bladder pain syndrome,30
an entity associated with the incidence of FM.31 Further, women
with FM who had a hysterectomy with or without oophorectomy
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were recently shown to have worse symptom severity than those
without hysterectomy.32 In an additional study of female FM
patients, not only was there a greater frequency of women who
had received a hysterectomy versus those who had not, but 90%
of the FM patients with hysterectomies reported receiving the
surgery before the onset of FM.33 Having FM with a previous
history of a hysterectomy was associated with a lower general
health status.32
In addition to sex hormones, research has implicated
other endocrine pathologies, such as those involving the
the hypothalamic–pituitary–adrenal (HPA) axis34–37 and
thyroid8,9,11,38–41 in FM. Research on the HPA axis in FM
has shown variations in cortisol levels,42,43 increased sensitivity to glucocorticoid feedback,44 and increased cortisol
release in response to a stressor.45 However, other studies
have failed to find evidence of cortisol dysregulation in
FM.36 Following a 3-week, multidisciplinary, FM treatment
program, improvements were noted in the function of HPA
axis, specifically cortisol and corticoid receptor levels.46
Altogether, the literature suggests that cortisol release may
be abnormal in FM, but the nature of the pathology remains
poorly understood at present.
In light of these previous studies, we sought to confirm
these findings in our cohort of female patients, analyzing
whether patients with FM had more autoimmune, endocrine, or gynecologic pathology than women of similar age
with CP of a similar duration. As recent studies of medical
comorbidities and FM included ethnically homogenous populations, with 97.4% of patients being non-Hispanic White,
we sought to confirm these findings in a more ethnically
diverse population.8,9 Specifically, this FM cohort is 53.8%
Hispanic. We additionally sought to provide more detailed
information on specific diagnoses and procedures, such as
hysterectomies and oophorectomies, than previous studies on
medical comorbidities in FM.8,9 We examined the relationship
between onset of pain and the onset of other disorders. This
was accomplished by looking at the timing of pain onset
and date of hysterectomy or oophorectomy. In addition to
endocrine and gynecologic variables, we also measured the
prevalence of other disorders frequently comorbid with FM,
such as psychiatric illness, chronic fatigue syndrome, and
irritable bowel syndrome.

Materials and methods
Screening
We screened all patients seen in 2009–2010 in a specialty FM
clinic and in a CP management clinic at an academic medical
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center for inclusion in the study. All patients who saw either
of the two physicians in the FM clinic or general CP clinic
were screened electronically. Patients were excluded if they
were men or had a cancer-related pain condition as their
primary diagnosis. A second group of patients was excluded
if they had pain for less than 6 months, a myofascial pain
component without an FM diagnosis, or a medical record
with insufficient documentation regarding pain diagnosis.
Myofascial pain was used as an exclusion criterion due to
concern over overlap with FM. The most common diagnoses among patients with CP included osteoarthritis and
lower back pain. These patients did not meet the criteria for
FM. A diagnosis of FM was made based on the previously
published American College of Rheumatology 1990 criteria
which includes the use of tender points.47 Approval to conduct
this study was granted by the institutional review board of
the University of Miami. A waiver of informed consent was
granted for this retrospective chart review.

Chart review
Charts were reviewed by the principal author (LB) and
three medical residents. All charts reviewed by the residents
were reviewed at least twice, and inconsistencies between
reviewers were identified and resolved by re-reviewing
the charts. Ten percent of the charts reviewed by LB and
by a resident were assessed for interrater reliability, which
exceeded 90%.
For each participant, data were gathered on diagnosis,
year of pain onset, medical comorbidities, psychiatric
comorbidities, surgical history, and date of hysterectomy,
oophorectomy, or cystectomy. In addition to obtaining

information from the physician’s notes, information on
specific aspects of the medical history (previous surgeries, dates of surgeries, date of pain onset, and psychiatric
diagnoses) from self-report medical history questionnaires
was used when available. The diagnosis of FM was based
on the physician note, while self-report medical history
questionnaires and registration papers used for patients
enrolling in the clinic, provided additional past medical
history or clarifications of the physician note. The most difficult information to collect was the date of pain onset and
dates of surgical procedures due to a lack of documentation.
There was a special issue with the psychiatric data, as there
were concerns that it was assessed with greater frequency
as a matter of clinical practice in the FM clinic. Due to
concerns over potential bias regarding the psychiatric data,
all analyses in this study were run with and without the
psychiatric data included. Though data were collected on
most medical comorbidities, the focus of data collection
was on endocrine, autoimmune, gynecologic, and psychiatric diagnoses. Grouping of diagnoses into variables is
delineated in Table 1. Gynecologic surgeries potentially
involving the ovaries were analyzed individually and collectively to account for heterogeneity of documentation
(eg, hysterectomy, hysterectomy + oophorectomy, and
hysterectomy + oophorectomy + cystectomy). This analysis
additionally allowed for a progressively more inclusive
method for identifying gynecologic procedures, with hysterectomy + oophorectomy + cystectomy being the most
inclusive cohort.
Data were also collected on hypertension, cholecystectomy, and conditions frequently comorbid with FM, such

Table 1 Diseases included in each pathology grouping
Variable

Chart diagnoses included

Autoimmune

Systemic lupus erythematosus, Rheumatoid arthritis,
Sjogren’s syndrome, Multiple sclerosis, CREST,
Polymyalgia rheumatica

Scleroderma, Idiopathic thrombocytopenic purpura,
Ulcerative colitis, Sarcoidosis, psoriasis, Pernicious
anemia

Total thyroid

Hashimoto’s disease, Hypothyroidism, Grave’s disease,
Hyperthyroidism

Goiter, Thyroid nodule, Thyroidectomy

Total psychiatric

Depression, Anxiety

Schizoaffective disorder, Schizophrenia

Total endocrine

Pituitary microadenoma, Hypopituitarism, Adrenalectomy,
Adrenal insufficiency, Parathyroidectomy

Parathyroid adenoma, Pineal tumor, Neuroendocrine
tumor

Total gynecologic

Hysterectomy, Oophorectomy, Endometriosis,
Endometrial hyperplasia, Polycystic ovarian syndrome,
Uterine fibroid, Fibroid removal, Ovarian cyst rupture

Ovarian cystectomy, Myomectomy, Uterotomy,
Endometrial ablation, Cervical polyp removal,
Uterine cancer, Uterine rupture

Gynecologic surgery

Hysterectomy, Oophorectomy, Fibroid removal,
Ovarian cystectomy, Myomectomy

Uterotomy, Endometrial ablation, Cervical polyp removal

Abbreviations: CREST, calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.
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as chronic fatigue syndrome and irritable bowel syndrome.
Hypertension and cholecystectomy were selected because
they are commonly occurring conditions and were mostly
unrelated to the hypothesized relationships in the study, and
thus serve as a form of control variable to assess whether
or not patients with FM had more of all diagnoses or if the
increased diagnostic burden was specific to the hypothesized
conditions.

Statistical analyses
All statistical analyses in the study were made using Statistical Package for the Social Sciences for Windows version
19.0 software (IBM Corporation, Armonk, NY, USA). Two
logistic regression analyses were run. The first logistic regression model included three binary, categorical, predictor variables: history of autoimmune disorder, history of endocrine
disorder, and history of gynecologic disorder of surgery. The
second model included these three variables plus a history of
psychiatric disorder. All variables were included in a single
block with forced entry into the model.
In essence, the logistic regression analyses served as
omnibus tests to determine if autoimmune, endocrine,
gynecologic, and psychiatric disorders were independently
associated with the diagnosis of FM. Chi-square analyses
were used to look with more detail at the difference in prevalence of disease pathology across groups. The significance
of these tests was defined as P#0.05 for a priori tests and as
P#0.01 for post hoc tests to correct for multiple comparisons.
The relationship between the timing of pain onset and the
timing of hysterectomy/oophorectomy was analyzed for the
subset of patients for whom such data were available (n=93).
Additionally, Mann–Whitney U tests were used to assess
if there were differences in the amount of comorbidities
between FM and CP participants.

Results
A total of 335 female patients were included in the study, with
219 in the FM group and 116 in the CP group. After excluding the nine patients who were not categorized as Caucasian,
African-American, or Hispanic, analyses revealed significant
differences in the ethnic composition of the FM and CP
groups (χ2=17.6; P,0.001). The percentage of Caucasian
patients as a total of the FM and CP groups was consistent
(34.2% versus 34.9%, respectively). However, a larger percentage of Hispanics were in the FM group than in the CP
group (53.8% versus 36.8%, respectively). In contrast, more
African-Americans were members of the CP group than of
the FM group (28.9% versus 11.3%, respectively). The mean
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(standard deviation) age for the FM group was 52.66 (12.3)
and that of the CP group was 52.5 (13.3). No differences
between groups were found by age (P=0.88) or years since
pain onset (P=0.55).

Logistic regression modeling
In the first logistic regression model, all three variables
(autoimmune, total endocrine, total gynecologic) were
significantly associated with the FM diagnosis (Table 2).
When psychiatric history was included in the model, a history of autoimmune or endocrine disorders continued to be
independently associated with a diagnosis of FM; however,
a history of a gynecologic disorder or surgery did not remain
significant.

Medical comorbidities
Autoimmune disorders, hypothyroidism, total thyroid, total
endocrine, total gynecologic, depression, and total diseases
included in each pathology grouping were significantly more
frequent in the FM group. No differences in diabetes and
hypertension were found between groups. Chronic fatigue
syndrome and irritable bowel syndrome were more common
in the FM than in the CP group. Exact proportions and gross
P-values are listed in Table 3.

Surgical history and relationship of
hysterectomy/oophorectomy with pain
onset

In terms of surgical history, hysterectomy + oophorectomy,
hysterectomy + oophorectomy + cystectomy, and total
gynecologic surgeries occurred more frequently in the FM
group. Across all participants with a history of hysterectomy or oophorectomy, the procedure preceded pain onset
in 73.1% of cases. On average, surgery occurred 8.3 (12.8)
years before pain onset. The range was from surgery occurring 43 years before pain onset to surgery occurring 19 years
Table 2 Logistic models predicting a diagnosis of fibromyalgia
β

OR (95% CI)

P-value

0.83
0.82
0.48

2.29 (1.12–4.70)
2.27 (1.26–4.10)
1.62 (1.02–1.59)

0.02
0.007
0.04

1.10
0.79
0.28
1.49

3.01 (1.40–6.43)
2.21 (1.19–4.11)
1.32 (0.80–2.19)
4.45 (2.69–7.35)

0.005
0.01
0.27
0.001

Model 1
Autoimmune
Total endocrine
Total gynecologic
Model 2
Autoimmune
Total endocrine
Total gynecologic
Total psychiatric

Abbreviations: CI, confidence interval; OR, odds ratio.
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Table 3 Proportion of patients with comorbidities by group
Fibromyalgia
(n=219)
Endocrine and autoimmune comorbidities
Autoimmune disorders
19.2%
44.7%
Endocrine + thyroid + diabetes
Diabetes
24.2%
 Any thyroid
27.4%
  Hypothyroid
21.5%
   Thyroidectomy
4.6%
30.1%
 Endocrine + thyroid
 Endocrine (no thyroid)
4.1%
Gynecologic comorbidities
Any gynecologic surgery or
54.8%
illness
Any gynecologic surgery
51.6%
Hysterectomy
39.3%
Hysterectomy/oophorectomy
43.4%
Hysterectomy/oophorectomy/
45.7%
cystectomy
Other comorbidities
Hypertension
45.7%
Cholecystectomy
17.8%
Irritable bowel syndrome
9.6%
Chronic fatigue syndrome
5.5%
Psychiatric comorbidities
71.7%
Depression + severe mental
illness
Depression
66.2%

9.5%*
34.6%*
19.8%
14.7%**
11.2%*
1.7%
15.5%**
1.7%

In the FM group, the peak of the distribution occurs
with surgeries occurring in the 4 (mean 7.7, median 3.5)
years just before pain onset or in the year after pain onset
(Figure 1). That perioperative time period accounts for 47.1%
of the hysterectomies and oophorectomies in FM patients.
In contrast, the same period accounts for 24.0% of surgeries in CP patients (mean 9.1, median 12 years). In contrast
with the FM patients, the distribution of the timing between
pain onset and time of surgery in CP patients appears to be
more random.

39.7%**

Aggregates across domains

Chronic pain
(n=116)

38.8%*
30.2%
30.2%*
31.9%*

42.2%
16.4%
0.9%**
0.0%**
37.1%**
35.3%**

Notes: *P#0.05; **P#0.01.

after pain onset. When the distributions between FM and CP
groups are displayed, there is a noticeable difference in the
shape of the distributions (Figures 1 and 2). Of note, 25 and
12 patients were excluded from the FM group and control
group, respectively, as the time of hysterectomy was not
available in the medical records.

Aggregates for each participant were calculated for endocrine, gynecologic, and autoimmune disorders. Data were
coded in a binary fashion for each type of disorder (endocrine, gynecologic, and autoimmune) for this analysis. The
maximum potential score was 3. For instance, if a participant
had an autoimmune diagnosis and an endocrine diagnosis,
then the subject would receive a score of 2. An individual
with two endocrine diagnoses would only receive a score
of 1. An additional set of analyses was conducted including
endocrine, gynecologic, and autoimmune plus psychiatric
diagnosis. Mann–Whitney U tests showed significant differences between the FM and CP groups, both when the analyses
included only endocrine, gynecologic, and autoimmune
diagnoses (U=9,339; P,0.001) and also when psychiatric
diagnoses were included (U=7,556; P,0.001). Individuals in
the FM group were 2.4 times more likely to have more than
one endocrine, gynecologic, or autoimmune diagnosis (see
Figure 3). When including psychiatric diagnoses, individuals
in the FM group were 4.0 times more likely to have three or
more diagnoses (Figure 4).
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Figure 1 Hysterectomy/oophorectomy and pain onset in fibromyalgia (n=68).
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Figure 2 Hysterectomy/oophorectomy and pain onset in chronic pain (n=25).

Discussion
This study confirmed previous findings that autoimmune,
gynecologic, endocrine, and total medical comorbidities are
elevated in women with FM, even in an ethnically diverse
cohort. We additionally demonstrate that there may be a temporal relationship between pain onset and timing of hysterectomy/oophorectomy. Further, we found that carrying multiple
diagnoses was more common in the FM group than in the
control group. As our control group consisted of women of a
similar age with CP for a similar amount of time, differences
between the groups may be inferred to be disease-related and
not age-related or pain-related. Our control cohort consisted
of CP patients, a majority of whom had lower back pain and/
or osteoarthritis, as opposed to rheumatoid arthritis patients
as in previous studies. Given the potentially important role
of autoimmunity in the pathogenesis of FM,48 a CP cohort
likely serves as a more meaningful control than a rheumatoid
arthritis control group.

Our results regarding the increased prevalence of gynecologic, endocrine, and psychiatric disorders were remarkably similar to the findings of disease prevalence reported
by Wolfe et al. 9 This similarity in prevalence is more
noteworthy given the demographic differences in ethnicity
between the two study populations, thereby increasing the
generalizability of these findings. Altogether, the data suggest
that our study’s findings of increased endocrine, autoimmune, gynecologic, and psychiatric comorbidities in FM are
specific and not due to age, ethnicity, or an increase in all
diagnoses or procedures. The finding that hysterectomies are
more common in women with FM has been demonstrated
previously.28,29 Likewise, hysterectomies were related to
greater symptom severity.32
Hysterectomies are the second most common surgery
among reproductive-aged women,49 with more than onethird of US women having had a hysterectomy by the age
of 60 years.50 Therefore, if hysterectomies are a contributor

60%
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50%
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30%

40%

25%

30%
CP
20%

FM

10%
0%

CP

15%

FM

10%
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0

1

2

3

Comorbid conditions (n)
Figure 3 Number of comorbid endocrine, gynecologic, and autoimmune
conditions.
Abbreviations: CP, chronic pain; FM, fibromyalgia.
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Figure 4 Number of comorbid endocrine, gynecologic, autoimmune, and psychiatric
conditions.
Abbreviations: CP, chronic pain; FM, fibromyalgia.
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to the development of FM, then why is the prevalence of
FM so much lower than the prevalence of hysterectomies?
Though genetic differences or pre-disease environmental
factors likely play a role in who develops FM, one possible
answer to the question of who develops FM is supported by
the cumulative burden data. The data show that the presence
of only one autoimmune, endocrine, or gynecologic condition is no more common in FM than in the CP control group;
however, participants who had more than one condition were
significantly more likely to have FM. This finding is even
more pronounced when the psychiatric data are included
as well.
An alternative explanation for our study findings is
that a common cause is responsible for the increase in
autoimmune, gynecologic, endocrine, and psychiatric
comorbidities. For instance, dysfunction at the level of
the hypothalamus or the pituitary could be responsible
for most of those disorders. Previous review articles have
documented that hypothalamic-pituitary dysfunction is
implicated in gynecologic51,52 and psychiatric disorders,53,54
while there additionally appears to be HPA axis abnormalities in autoimmune disease.55,56 By definition, dysfunction
at the level of the hypothalamus or the pituitary involves
endocrine pathology. Central pathology of the hypothalamus
or pituitary could explain some of the frequent symptoms in
FM involving sleep pathology,57,58 fatigue,57 and cognitive
complaints,58,59 as all have been related to hypothalamic
or pituitary dysfunction or the downstream effects of such
dysfunction.
The increased amount of gynecologic pathology in FM,
as well as the relationship between the timing of gynecologic
surgery and pain onset, indicates that a hypoestronergic
state may contribute to increased pain perception. Despite
striking sex differences in the prevalence of FM and other
CP conditions, the effects of estrogen on pain perception are
poorly understood. A relatively recent review of estrogen and
pain highlighted the effects of estrogen on multiple sites and
systems involved in nociceptive processing, including the
hypothalamus, pituitary gland, descending noxious inhibitory
controls, sympathetic nervous system, primary afferents, and
the dorsal horn of the spinal cord.60 Estrogen has also been
shown to modulate the capsaicin (TRPV1) receptor61,62 and
the dorsal root ganglia.63 Data on the peak prevalence of
FM approximately overlap with menopause, with one study
showing a significant increase in prevalence in women after
the age of 50 years,1 and a second study showing a peak
prevalence between 55 and 64 years.64 Thus, further study of
the relationship between estrogen and FM is warranted.

Journal of Pain Research 2015:8
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The primary limitation of the study is the limited standardization of the manner in which data were collected in
the two separate pain clinics due to the study’s retrospective
nature. In both clinics, the nursing staff take a medical history in a similar fashion; however, there is more of a focus
on psychiatric comorbidity in the FM clinic. Consequently,
the identified differences between the two groups may be an
artifact of a lack of standardization in data collection methods,
particularly with respect to psychiatric data. The most likely
flaw would be an underrepresentation of psychiatric illness
in one of the groups due to insufficient assessment. This is
the reason that all data are presented in this paper with and
without psychiatric data. It should be noted that the rates of
depression found in the participants are generally consistent
with a recent study of comorbidities in FM,9 which lends
greater credence to the psychiatric data presented in the paper.
Additionally, while both clinics diagnosed FM based on the
American College of Rheumatology criteria from 1990 that
uses tender points as a means of making a diagnosis, the tender
point method is not an ideal means of diagnosing FM and has
thus been replaced in more recent proposed guidelines.65 An
additional limitation is that it was often difficult to find the
desired information. For instance, the data related to the timing
of surgery in relation to pain onset could only be identified
in approximately half of the patients. Further, information
related to hysterectomy was limited, such that it was impossible to determine if ovaries were conserved or removed.
This lack of specific documentation occurred in both groups
and thus likely did not introduce bias. Similarly, the use of
patient reported pain onset is not an entirely reliable outcome
measure. In the future, a prospective study with standardized
data collection methods including detail as to the timing and
nature of surgical procedures will allow for more thorough
study of the issues raised in this paper.
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